SCHOLARLY PUBLICATION

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

📖 European Journal of Cancer → 📅 2006-04-19 🔗 DOI: 10.1016/j.ejca.2006.01.030

View Journal Profile → View Official Paper ↗

📄 Abstract

The abstract has not yet been added. Use the official source link for the complete publication record.

ℹ️ Publication Details

Journal: European Journal of Cancer
Published: 2006-04-19
DOI: 10.1016/j.ejca.2006.01.030
OpenAlex: W2068079378
Access: Via publisher

📋 Cite This Paper

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T. van Oosterom, Jean‐Yves Blay, Serge Leyvraz, Michel S. Stul, Paolo Giovanni Casali, John Raymond Zalcberg, Jaap Verweij, Martine Van Glabbeke, Anne Hagemeijer, Ian Robert Judson (2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2006.01.030

🔬 Related Research Papers

European Journal of Cancer

General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States

Sandra Nolte, Gregor Liegl et al. 2018-12-19 · Read paper → European Journal of Cancer

The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

Benjamin Aaron Alman, Steven Attia et al. 2020-01-28 · Read paper → European Journal of Cancer

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

Alexander Stratigos, Claus Garbe et al. 2015-07-25 · Read paper → European Journal of Cancer

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Sigbjørn Smeland, Stefan S. Bielack et al. 2019-01-27 · Read paper → European Journal of Cancer

Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

Henrike E. Karim‐Kos, Esther de Vries et al. 2008-03-03 · Read paper → European Journal of Cancer

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Roger Stupp, Eric T. Wong et al. 2012-05-17 · Read paper →

📄 Abstract

🔬 Related Research Papers

General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States

The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task

The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study

Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors

Rare cancers are not so rare: The rare cancer burden in Europe

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality